118 lines
114 KiB
Text
118 lines
114 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK259186">
|
|
<meta name="ncbi_domain" content="mlprobe">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK259186/?report=reader">
|
|
<meta name="ncbi_pagename" content="Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/mlprobe/ml328/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/mlprobe/ml327/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/mlprobe/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Probe Reports from the NIH Molecular Libraries Program [Internet]">
|
|
<meta name="citation_title" content="Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2014/09/18">
|
|
<meta name="citation_author" content="Thomas S. Dexheimer">
|
|
<meta name="citation_author" content="Andrew S. Rosenthal">
|
|
<meta name="citation_author" content="Qin Liang">
|
|
<meta name="citation_author" content="Junjun Chen">
|
|
<meta name="citation_author" content="Mark A. Villamil">
|
|
<meta name="citation_author" content="Edward H. Kerns">
|
|
<meta name="citation_author" content="Anton Simeonov">
|
|
<meta name="citation_author" content="Ajit Jadhav">
|
|
<meta name="citation_author" content="Zhihao Zhuang">
|
|
<meta name="citation_author" content="David J. Maloney">
|
|
<meta name="citation_pmid" content="25506968">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK259186/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Thomas S. Dexheimer">
|
|
<meta name="DC.Contributor" content="Andrew S. Rosenthal">
|
|
<meta name="DC.Contributor" content="Qin Liang">
|
|
<meta name="DC.Contributor" content="Junjun Chen">
|
|
<meta name="DC.Contributor" content="Mark A. Villamil">
|
|
<meta name="DC.Contributor" content="Edward H. Kerns">
|
|
<meta name="DC.Contributor" content="Anton Simeonov">
|
|
<meta name="DC.Contributor" content="Ajit Jadhav">
|
|
<meta name="DC.Contributor" content="Zhihao Zhuang">
|
|
<meta name="DC.Contributor" content="David J. Maloney">
|
|
<meta name="DC.Date" content="2014/09/18">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK259186/">
|
|
<meta name="description" content="Advances in pharmacological approaches to target the ubiquitin–proteasome system have revealed several potential new molecular targets within the ubiquitin machinery. Likewise, the functional consequences of ubiquitination and deubiquitination have recently been linked to a wide variety of critical biological processes well beyond just protein disposal [1]. For example, the deubiquitining enzyme, ubiquitin-specific protease 1 (USP1), in association with its WD40 binding partner, UAF1 (USP1-associated factor 1), is a known regulator of DNA damage response and has been suggested as a promising target to improve the efficacy of the commonly used DNA damaging drugs by modulating the cancer cells' ability to repair or tolerate DNA lesions [2-7]. To further evaluate the therapeutic potential of targeting the USP1/UAF1 deubiquitinase complex, we conducted a quantitative high-throughput screen and a subsequent medicinal chemistry optimization campaign in pursuit of small molecules that inhibit USP1/UAF1. Herein, we describe the discovery and optimization of ML323, a probe molecule that displays reversible, nanomolar inhibitory activity and excellent selectivity toward USP1/UAF1. In addition, ML323 potentiates the cytotoxicity of cisplatin and increases endogenous monoubiquitination levels of both PCNA and FANCD2, two known cellular targets of USP1/UAF1 [8]. Lastly, ML323 possesses a promising in vitro ADME profile, suggesting its suitability for further testing in PK/PD studies.">
|
|
<meta name="og:title" content="Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Advances in pharmacological approaches to target the ubiquitin–proteasome system have revealed several potential new molecular targets within the ubiquitin machinery. Likewise, the functional consequences of ubiquitination and deubiquitination have recently been linked to a wide variety of critical biological processes well beyond just protein disposal [1]. For example, the deubiquitining enzyme, ubiquitin-specific protease 1 (USP1), in association with its WD40 binding partner, UAF1 (USP1-associated factor 1), is a known regulator of DNA damage response and has been suggested as a promising target to improve the efficacy of the commonly used DNA damaging drugs by modulating the cancer cells' ability to repair or tolerate DNA lesions [2-7]. To further evaluate the therapeutic potential of targeting the USP1/UAF1 deubiquitinase complex, we conducted a quantitative high-throughput screen and a subsequent medicinal chemistry optimization campaign in pursuit of small molecules that inhibit USP1/UAF1. Herein, we describe the discovery and optimization of ML323, a probe molecule that displays reversible, nanomolar inhibitory activity and excellent selectivity toward USP1/UAF1. In addition, ML323 potentiates the cytotoxicity of cisplatin and increases endogenous monoubiquitination levels of both PCNA and FANCD2, two known cellular targets of USP1/UAF1 [8]. Lastly, ML323 possesses a promising in vitro ADME profile, suggesting its suitability for further testing in PK/PD studies.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK259186/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-mlprobe-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/mlprobe/ml323/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK259186/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8CD4497D66B82100000000000E000D.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK259186/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/mlprobe/ml328/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex</div><div class="j">Probe Reports from the NIH Molecular Libraries Program [Internet]</div></div><div class="tail"><a href="/books/n/mlprobe/ml327/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK259186/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK259186/&text=Discovery%20of%20ML323%20as%20a%20Novel%20Inhibitor%20of%20the%20USP1%2FUAF1%20Deubiquitinase%20Complex"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/mlprobe/?report=reader">Title Information</a><a href="/books/n/mlprobe/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK259186/?report=classic">Switch to classic view</a><a href="/books/NBK259186/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK259186%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8CD4497D66B82100000000000E000D.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK259186_"><span class="title" itemprop="name">Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex</span></h1><p class="contribs">Dexheimer TS, Rosenthal AS, Liang Q, et al.</p><p class="fm-aai"><a href="#_NBK259186_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p>Advances in pharmacological approaches to target the ubiquitin–proteasome system have revealed several potential new molecular targets within the ubiquitin machinery. Likewise, the functional consequences of ubiquitination and deubiquitination have recently been linked to a wide variety of critical biological processes well beyond just protein disposal [<a class="bibr" href="#ml323.r1" rid="ml323.r1">1</a>]. For example, the deubiquitining enzyme, ubiquitin-specific protease 1 (USP1), in association with its WD40 binding partner, UAF1 (USP1-associated factor 1), is a known regulator of DNA damage response and has been suggested as a promising target to improve the efficacy of the commonly used DNA damaging drugs by modulating the cancer cells' ability to repair or tolerate DNA lesions [<a class="bibr" href="#ml323.r2" rid="ml323.r2">2</a>-<a class="bibr" href="#ml323.r7" rid="ml323.r7">7</a>]. To further evaluate the therapeutic potential of targeting the USP1/UAF1 deubiquitinase complex, we conducted a quantitative high-throughput screen and a subsequent medicinal chemistry optimization campaign in pursuit of small molecules that inhibit USP1/UAF1. Herein, we describe the discovery and optimization of <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=abstract&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>, a probe molecule that displays reversible, nanomolar inhibitory activity and excellent selectivity toward USP1/UAF1. In addition, <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=abstract&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> potentiates the cytotoxicity of cisplatin and increases endogenous monoubiquitination levels of both PCNA and FANCD2, two known cellular targets of USP1/UAF1 [<a class="bibr" href="#ml323.r8" rid="ml323.r8">8</a>]. Lastly, <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=abstract&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> possesses a promising <i>in vitro</i> ADME profile, suggesting its suitability for further testing in PK/PD studies.</p></div><div class="h2"></div><p><b>Assigned Assay Grant #:</b> R03 DA030552</p><p><b>Screening Center Name & PI:</b> NIH Chemical Genomics Center, Christopher P. Austin</p><p><b>Chemistry Center Name & PI:</b> NIH Chemical Genomics Center, Christopher P. Austin</p><p><b>Assay Submitter & Institution:</b> Zhihao Zhuang, Department of Chemistry and Biochemistry, University of Delaware</p><p><b>PubChem Summary Bioassay Identifier (AID):</b>
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/504878" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">504878</a></p><div id="ml323.s1"><h2 id="_ml323_s1_">Probe Structure & Characteristics</h2><div id="ml323.f1" class="figure"><div class="graphic"><img src="/books/NBK259186/bin/ml323f1.jpg" alt="Image ml323f1" /></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml323t1"><a href="/books/NBK259186/table/ml323.t1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figml323t1" rid-ob="figobml323t1"><img class="small-thumb" src="/books/NBK259186/table/ml323.t1/?report=thumb" src-large="/books/NBK259186/table/ml323.t1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ml323.t1"><a href="/books/NBK259186/table/ml323.t1/?report=objectonly" target="object" rid-ob="figobml323t1">Table</a></h4></div></div></div><div id="ml323.s2"><h2 id="_ml323_s2_">1. Recommendations for Scientific Use of the Probe</h2><p><a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>, with its ability to potently and selectively inhibit USP1/UAF1 both <i>in vitro</i> and in a cellular context, enables biologists the evaluation of the USP1/UAF1 deubiquitinase complex as a target for therapeutic development. Ubiquitin-specific Protease 1 (USP1) is a deubiquitinating (DUB) enzyme implicated in DNA damage response through modulation of the ubiquitination levels of key proteins, PCNA and FANCD2, which play important roles in translesion synthesis and Fanconi anemia pathways, respectively [<a class="bibr" href="#ml323.r8" rid="ml323.r8">8</a>]. Subsequent secondary and tertiary assay results also suggest that <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> inhibitor may be used in combination with known DNA damaging agents, such as cisplatin, to potentiate the cytotoxicity [<a class="bibr" href="#ml323.r9" rid="ml323.r9">9</a>]. In addition, <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> addresses the limitations exhibited by the current probes. GW7647 and Pimozide, the first annotated USP1 inhibitors, display fairly promiscuous PubChem activity profile with a 9.9% and 12.0% hit rate respectively; while another compound C527 (Publication no. WO/2011/137320) also display limited selectivity across the deubiquitinase families (USP12/46, IC<sub>50</sub> = 5.97 µM; USP5, IC<sub>50</sub> = 1.65 µM; UCL-H3, IC<sub>50</sub> = 2.18 µM). Therefore, given its favorable biochemical and physicochemical attributes, <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> can be used by the research community to interrogate USP1 biology <i>in vivo</i>.</p></div><div id="ml323.s3"><h2 id="_ml323_s3_">2. Materials and Methods</h2><p><b>General Methods for Chemistry</b>. All air or moisture sensitive reactions were performed under positive pressure of nitrogen with oven-dried glassware. Anhydrous solvents such as dichloromethane, <i>N,N</i>-dimethylforamide (DMF), acetonitrile, methanol and triethylamine were purchased from Sigma-Aldrich. Preparative purification was performed on a Waters semi-preparative HPLC system. The column used was a Phenomenex Luna C18 (5 micron, 30 × 75 mm) at a flow rate of 45 mL/min. The mobile phase consisted of acetonitrile and water (each containing 0.1% trifluoroacetic acid). A gradient of 10% to 50% acetonitrile over 8 minutes was used during the purification. Fraction collection was triggered by UV detection (220 nm). Analytical analysis was performed on an Agilent LC/MS (Agilent Technologies, Santa Clara, CA). Method 1: A 7 minute gradient of 4% to 100% Acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with an 8 minute run time at a flow rate of 1 mL/min. A Phenomenex Luna C18 column (3 micron, 3 × 75 mm) was used at a temperature of 50 °C. Method 2: A 3 minute gradient of 4% to 100% Acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with a 4.5 minute run time at a flow rate of 1 mL/min. A Phenomenex Gemini Phenyl column (3 micron, 3 × 100 mm) was used at a temperature of 50° C. Purity determination was performed using an Agilent Diode Array Detector for both Method 1 and Method 2. Mass determination was performed using an Agilent 6130 mass spectrometer with electrospray ionization in the positive mode. <sup>1</sup>H NMR spectra were recorded on Varian 400 MHz spectrometers. Chemical shifts are reported in ppm with undeuterated solvent (DMSO-d<sub>6</sub> at 2.49 ppm) as internal standard for DMSO-d<sub>6</sub> solutions. All of the analogs tested in the biological assays have purity greater than 95%, based on both analytical methods. High resolution mass spectrometry was recorded on Agilent 6210 Time-of-Flight LC/MS system. Confirmation of molecular formula was accomplished using electrospray ionization in the positive mode with the Agilent Masshunter software (version B.02).</p><p><b>Cell lines and culture conditions.</b> The human non-small cell lung cancer (NSCLC) H596 was cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS) at 37 °C and 5% CO<sub>2</sub>. The human embryonic kidney 293T (HEK293T), human osteosarcoma U2OS, and human colon cancer HCT116 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS at 37 °C and 5% CO<sub>2</sub>. All culture mediums contain 100 units/mL penicillin and 0.1 mg/mL streptomycin as antibiotics.</p><p><b>Reagents and antibodies sources.</b> Ubiquitin-rhodamine110, K63-linked diubiquitin, full length USP7 (HAUSP), USP5 (Isopeptidase T), USP8, and the catalytic domain of USP2 (a. a. 259 – 605) were purchased from Boston Biochem. USP1/UAF1 and USP46/UAF1 complexes were generated as previously described [<a class="bibr" href="#ml323.r9" rid="ml323.r9">9</a>]. Both human anti-PCNA and anti-FANCD2 antibodies were from Santa Cruz. USP1 antibody was from Abcam. HA-tag and HRP-conjugated anti-mouse antibodies were from Sigma-Aldrich. HRP-conjugated anti-rabbit secondary antibody was from Bio-Rad.</p><div id="ml323.s4"><h3>2.1. Assays</h3><p><b>USP1/UAF1 qHTS assay (BioAssay <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651605" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651605</a>).</b> USP1/UAF1 activity was monitored in a fluorometric assay using ubiquitin-rhodamine110 (<a class="figpopup" href="/books/NBK259186/table/ml323.t2/?report=objectonly" target="object" rid-figpopup="figml323t2" rid-ob="figobml323t2">Table 1</a>). Enzymatic reactions were conducted in an assay buffer composed of 50 mM HEPES, pH 7.8, 0.5 mM EDTA, 100 mM NaCl, 1 mM TCEP, 0.1 mg/mL BSA, and 0.01% Tween-20 that contained 1 nM USP1/UAF1. Each individual compound was tested at five concentrations in the range of 0.46 to 115 µM. The plates were incubated for 15 min to attain equilibrium, and then the enzymatic reaction was initiated by dispensing 150 nM Ub-Rho solution. The plates were directly transferred to a ViewLux high-throughput CCD imager (PerkinElmer), where kinetic measurements of rhodamine fluorescence were acquired using a 480 nm excitation/540 nm emission filter set. The change in fluorescence intensity over a 5-minute reaction period (typically associated with less than 10% substrate conversion) was normalized against no-inhibitor and no-enzyme controls and the resulting percent inhibition data were fitted to a sigmoidal dose response using a four-parameter Hill equation. All screening operations were performed on a fully integrated robotic system (Kalypsys Inc., San Diego, CA) as described elsewhere. Plates containing DMSO only were included approximately every 50 plates throughout the screen to monitor any systematic trend in the assay signal associated with reagent dispenser variation or decrease in enzyme specific activity.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml323t2"><a href="/books/NBK259186/table/ml323.t2/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figml323t2" rid-ob="figobml323t2"><img class="small-thumb" src="/books/NBK259186/table/ml323.t2/?report=thumb" src-large="/books/NBK259186/table/ml323.t2/?report=previmg" alt="Table 1. USP1/UAF1 qHTS protocol." /></a><div class="icnblk_cntnt"><h4 id="ml323.t2"><a href="/books/NBK259186/table/ml323.t2/?report=objectonly" target="object" rid-ob="figobml323t2">Table 1</a></h4><p class="float-caption no_bottom_margin">USP1/UAF1 qHTS protocol. </p></div></div><p><b>K63-linked diubiquitin gel assay (BioAssay <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651621" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651621</a> [USP1/UAF1], <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651622" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651622</a> [USP46/UAF1], <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651623" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651623</a> [USP8], <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651624" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651624</a> [USP7], <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651625" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651625</a> [USP5], and <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651626" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651626</a> [USP]).</b> Inhibitors at varied concentrations were added to the assay containing USP at appropriate concentration (150 nM USP1/UAF1, 30 nM USP2, 15 nM USP5, 7.5 nM USP7, 255 nM USP8, and 600 nM USP46/UAF1) and 3 µM K63-linked diubiquitin in a buffer containing 50 mM HEPES pH 7.8, 0.1 mg/mL BSA, 0.5 mM EDTA and 1 mM DTT. After 1 hour at 37 °C, the reaction was quenched by the addition of Laemmli sample buffer. The reaction products were then separated on a 20% denaturing SDS-PAGE gel and stained with Coomassie Blue. The intensity of the individual diubiquitin and monoubiquitin bands were quantified using Quantity One software (Bio-Rad). The enzyme activity was normalized against no-inhibitor control and plotted against inhibitor concentration. The IC<sub>50</sub> value was determined by fitting the dose response curve to the equation below using GraphPad Prism (GraphPad Software), where <i>X</i> = Log[inhibitor]; <i>Y</i> is the enzyme activity in percent relative to control.</p><div class="pmc_disp_formula whole_rhythm clearfix" id="ml323.eq1"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col">
|
|
<math id="ml323.m1" display="block"><mrow><mi>Y</mi><mo>=</mo><msub><mi>Y</mi><mn>0</mn></msub><mo>+</mo><mfrac><mrow><msub><mi>Y</mi><mtext mathvariant="italic">max</mtext></msub><mo>−</mo><msub><mi>Y</mi><mn>0</mn></msub></mrow><mrow><mn>1</mn><mo>+</mo><msup><mrow><mn>10</mn></mrow><mrow><mi>X</mi><mo>−</mo><mtext mathvariant="italic">Log</mtext><mspace width="0.2em"></mspace><mi>I</mi><msub><mi>C</mi><mrow><mn>50</mn></mrow></msub></mrow></msup></mrow></mfrac></mrow></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div><p><b>Ki determination using diubiquitin gel assay.</b> The inhibition assay solution contained 150 nM USP1/UAF1, 7 – 80 µM K63-linked diubiquitin, and <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> at varied concentrations in a buffer containing 50 mM HEPES, pH 7.8, 0.1 mg/mL BSA, 0.5 mM EDTA, and 1 mM DTT. The reaction was incubated for 10 – 90 minutes at 37 °C, and then quenched by the addition of Laemmli sample buffer at the given time point. The reaction products were separated on a 20% denaturing SDS-PAGE gel and stained with Coomassie Blue. The intensity of the individual diubiquitin and monoubiquitin bands were quantified using Quantity One 4.3.1 (Biorad, Hercules, CA). The percentage of the conversion was determined and used to calculate the reaction rate. The Lineweaver-Burk plot was obtained by plotting 1/v against 1/[di-Ub] at four different inhibitor concentrations. For noncompetitive inhibition, Ki was determined by fitting the data to the equations shown below using Origin 8 (OriginLab Corp., Northampton, MA).</p><div class="pmc_disp_formula whole_rhythm clearfix" id="ml323.eq2"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col">
|
|
<math id="ml323.m2" display="block"><mrow><mtable><mtr><mtd><mrow><mfrac><mn>1</mn><mi>υ</mi></mfrac><mo>=</mo><mrow><mo>[</mo><mrow><mfrac><mrow><msub><mi>K</mi><mi>m</mi></msub></mrow><mrow><msub><mi>V</mi><mtext mathvariant="italic">max</mtext></msub></mrow></mfrac><mrow><mo>(</mo><mrow><mfrac><mn>1</mn><mrow><mo>[</mo><mi>S</mi><mo>]</mo></mrow></mfrac></mrow><mo>)</mo></mrow><mo>+</mo><mfrac><mn>1</mn><mrow><msub><mi>V</mi><mtext mathvariant="italic">max</mtext></msub></mrow></mfrac></mrow><mo>]</mo></mrow><mspace width="0.2em"></mspace><mrow><mo>(</mo><mrow><mn>1</mn><mo>+</mo><mfrac><mrow><mo stretchy="false">[</mo><mi>I</mi><mo stretchy="false">]</mo></mrow><mrow><msub><mi>K</mi><mi>i</mi></msub></mrow></mfrac></mrow><mo>)</mo></mrow></mrow></mtd></mtr><mtr><mtd><mrow><mtext>Slope</mtext><mo>=</mo><mfrac><mrow><msub><mi>K</mi><mi>m</mi></msub></mrow><mrow><msub><mi>V</mi><mtext mathvariant="italic">max</mtext></msub></mrow></mfrac><mspace width="0.2em"></mspace><mrow><mo>(</mo><mrow><mn>1</mn><mo>+</mo><mfrac><mrow><mo stretchy="false">[</mo><mi>I</mi><mo stretchy="false">]</mo></mrow><mrow><msub><mi>K</mi><mi>i</mi></msub></mrow></mfrac></mrow><mo>)</mo></mrow></mrow></mtd></mtr><mtr><mtd><mrow><mtext>Intercept</mtext><mo>=</mo><mfrac><mn>1</mn><mrow><msub><mi>V</mi><mtext mathvariant="italic">max</mtext></msub></mrow></mfrac><mspace width="0.2em"></mspace><mrow><mo>(</mo><mrow><mn>1</mn><mo>+</mo><mfrac><mrow><mo stretchy="false">[</mo><mi>I</mi><mo stretchy="false">]</mo></mrow><mrow><msub><mi>K</mi><mi>i</mi></msub></mrow></mfrac></mrow><mo>)</mo></mrow></mrow></mtd></mtr></mtable></mrow></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div><p><b>Reversibility assay (BioAssay AIDxxx).</b> The compound <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> at a concentration of ten times its IC<sub>50</sub> value was pre-incubated with 10 µM USP1/UAF1 at room temperature for 15 min. This solution was then diluted by 100-fold in assay buffer containing 50 mM HEPES, pH 7.8, 0.1 mg/mL BSA, 0.5 mM EDTA, and 1 mM DTT and incubated at room temperature for an additional 15 min. Next, 20 µM K63-linked diubiquitin was added into the solution and incubated at 37 °C for 10 min. Laemmli sample buffer was added to quench the reaction. The reaction products were then separated on a 20% denaturing SDS-PAGE gel and stained with Coomassie Blue. USP1/UAF1 incubated with DMSO was treated as 100% USP1/UAF1 activity. Rottlerin was utilized as an irreversible control inhibitor [<a class="bibr" href="#ml323.r9" rid="ml323.r9">9</a>].</p><p><b>Inhibition of the cellular activity of USP1/UAF1.</b> HEK293T or H596 cells were plated in 10 cm dishes and synchronized in S-phase with the double-thymidine block method as described previously [<a class="bibr" href="#ml323.r9" rid="ml323.r9">9</a>]. Then cells were treated with 100 µM cisplatin, 30 µM <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>, or 100 µM cisplatin plus 30 µM <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>. Negative control cells were treated with an equal volume of DMSO and saline (0.9% NaCl). After 6 hr at 37 °C, cells were harvested and lysed. Cell extracts were separated on SDS-PAGE and transferred to nitrocellulose membrane. The membranes were then blotted with PCNA antibody or FANCD2 antibody, followed by incubation with HRP-conjugated anti-mouse secondary antibody. Images were quantified in FluorChem Q software (Imgen technologies). Alternatively, HCT116 cells were plated in 6-well plates and allowed to adhere overnight. Cells were treated with the indicated concentrations of <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> and were incubated for an additional 6 hr. Western blot analysis using anti-PCNA antibody was performed as described above.</p><p><b>Cytoxicity and clonogenicity assays.</b> For cytotoxicity assays, 5 × 10<sup>3</sup> H596 cells were seeded in each well of the 96-well plate and grown for 24 hr in humidified incubator. Cells were initially treated with cisplatin or <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> individually for 48 hr to determine the EC<sub>50</sub> of each compound. In the combination assay, cisplatin was dissolved in saline solution and <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> was dissolved in DMSO. Equal volume of above solutions was added to each well and cells were incubated for 48 hr. Cells treated with equal volume of DMSO and saline were used as control and designated as 100% viability. The cell viability was measured by CCK-8 solution (Dojindo Molecular Technologies, Inc) as previously described [<a class="bibr" href="#ml323.r9" rid="ml323.r9">9</a>]. For the colony formation assay, H596 cells were seeded at the density of 200 cells per well in 6-well plates and grown overnight in humidified incubator. The medium was replaced with growth medium containing cisplatin and <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> at different concentrations individually or in combination. After 48 hr treatment, the medium was replaced with fresh growth medium and the plates were incubated for an additional 7-8 days to allow for colony formation. Cells were then fixed with methanol and stained with 0.1% crystal violet (Sigma-Aldrich). The number of colonies consisting of 50 or more cells was scored. Cells treated with equal volume of DMSO and saline were used as a control and designated as 100%. Colony numbers were determined from triplicate plates. Dose-response curves for cytotoxicity and colony formation assays were generated by using GraphPad Prism and analyzed using CalcuSyn (Biosoft) to calculate the combination index (CI), which was determined for the fraction of cells affected [<a class="bibr" href="#ml323.r10" rid="ml323.r10">10</a>] following addition of the fixed ratios of cisplatin and <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>.</p></div><div id="ml323.s5"><h3>2.2. Probe Chemical Characterization</h3><div id="ml323.f2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20ml323f2&p=BOOKS&id=259186_ml323f2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK259186/bin/ml323f2.jpg" alt="Image ml323f2" class="tileshop" title="Click on image to zoom" /></a></div><div class="caption"><p>*Purity >98% as determined by LC/MS and <sup>1</sup>H NMR analyses</p></div></div><p><b><i>N</i>-(4-(1H-1,2,3-triazol-1-yl)benzyl)-5-methyl-2-(2-isopropylphenyl)pyrimidin-4-amine (NCGC00262306-01):</b> LC-MS Retention Time: t<sub>1</sub> (Method 1) = 2.938 min and t<sub>2</sub> (Method 2) = 1.756 min; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.82 (dd, <i>J</i> = 7.9, 3.4 Hz, 1H), 8.02 – 7.93 (m, 2H), 7.76 (d, <i>J</i> = 1.4 Hz, 1H), 7.64 – 7.56 (m, 2H), 7.51 – 7.33 (m, 5H), 7.25 – 7.17 (m, 1H), 4.88 (d, <i>J</i> = 5.9 Hz, 2H), 3.19 (p, <i>J</i> = 6.8 Hz, 1H), 2.22 (s, 3H), 1.10 (d, <i>J</i> = 1.2 Hz, 3H), 1.09 – 1.07 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 162.02, 160.18, 148.00, 140.63, 138.03, 136.14, 134.35, 134.28, 131.89, 130.34, 129.25, 129.00, 126.61, 126.04, 122.04, 121.99, 120.74, 113.81, 44.62, 29.43, 23.95, 13.71, 13.67; HRMS (ESI) <i>m/z</i> (M+H)<sup>+</sup> calcd. for C<sub>23</sub>H<sub>25</sub>N<sub>6</sub>, 385.2135; found 385.2146.</p><div id="ml323.f3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Chemical%20stability%20of%20ML323%20measured%20as%20percent%20composition%20of%20probe%20molecule%20in%20aqueous%20solution%20at%20room%20temperature%20in%20(A)%20DPBS%20pH%207.4%20buffer%3B%20(B)%20USP1%2FUAF1%20assay%20buffer%20at%20pH%207.8%20(50%20mM%20HEPES%2C%200.5%20mM%20EDTA%2C%20100%20mM%20NaCl%2C%201%20mM%20TCEP%2C%200.1%20mg%2FmL%20BSA%2C%20and%200.01%25%20Tween-20)%3B%20(C)%20USP1%2FUAF1%20assay%20buffer%20at%20pH%202%20and%20(D)%20at%20pH%209%20buffer.&p=BOOKS&id=259186_ml323f3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK259186/bin/ml323f3.jpg" alt="Figure 1. Chemical stability of ML323 measured as percent composition of probe molecule in aqueous solution at room temperature in (A) DPBS pH 7.4 buffer; (B) USP1/UAF1 assay buffer at pH 7.8 (50 mM HEPES, 0.5 mM EDTA, 100 mM NaCl, 1 mM TCEP, 0.1 mg/mL BSA, and 0.01% Tween-20); (C) USP1/UAF1 assay buffer at pH 2 and (D) at pH 9 buffer." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Chemical stability of ML323 measured as percent composition of probe molecule in aqueous solution at room temperature in (A) DPBS pH 7.4 buffer; (B) USP1/UAF1 assay buffer at pH 7.8 (50 mM HEPES, 0.5 mM EDTA, 100 mM NaCl, 1 mM TCEP, 0.1 mg/mL BSA, and 0.01% Tween-20); (C) USP1/UAF1 assay buffer at pH 2 and (D) at pH 9 buffer</span></h3></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml323t3"><a href="/books/NBK259186/table/ml323.t3/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figml323t3" rid-ob="figobml323t3"><img class="small-thumb" src="/books/NBK259186/table/ml323.t3/?report=thumb" src-large="/books/NBK259186/table/ml323.t3/?report=previmg" alt="Table 2. List of the USP1/UAF1 deubiquitinase complex inhibitor probe ML323 and related analogs and their corresponding identification numbers." /></a><div class="icnblk_cntnt"><h4 id="ml323.t3"><a href="/books/NBK259186/table/ml323.t3/?report=objectonly" target="object" rid-ob="figobml323t3">Table 2</a></h4><p class="float-caption no_bottom_margin">List of the USP1/UAF1 deubiquitinase complex inhibitor probe ML323 and related analogs and their corresponding identification numbers. Their corresponding molecular structures are shown in Figure 2. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml323f4" co-legend-rid="figlgndml323f4"><a href="/books/NBK259186/figure/ml323.f4/?report=objectonly" target="object" title="Figure 2" class="img_link icnblk_img figpopup" rid-figpopup="figml323f4" rid-ob="figobml323f4"><img class="small-thumb" src="/books/NBK259186/bin/ml323f4.gif" src-large="/books/NBK259186/bin/ml323f4.jpg" alt="Figure 2. Structures of ML323 and five other analogs that have been submitted to the MLSMR." /></a><div class="icnblk_cntnt" id="figlgndml323f4"><h4 id="ml323.f4"><a href="/books/NBK259186/figure/ml323.f4/?report=objectonly" target="object" rid-ob="figobml323f4">Figure 2</a></h4><p class="float-caption no_bottom_margin">Structures of ML323 and five other analogs that have been submitted to the MLSMR. </p></div></div></div><div id="ml323.s6"><h3>2.3. Probe Preparation</h3><p>Preparation of N-(4-(1H-1,2,3-triazol-1-yl)benzyl)-5-methyl-2-(2-isopropylphenyl)pyrimidin-4-amine (<a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>) is a multi-step process illustrated in <a class="figpopup" href="/books/NBK259186/figure/ml323.f5/?report=objectonly" target="object" rid-figpopup="figml323f5" rid-ob="figobml323f5">Scheme 1</a> and summarized below.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml323f5" co-legend-rid="figlgndml323f5"><a href="/books/NBK259186/figure/ml323.f5/?report=objectonly" target="object" title="Scheme 1" class="img_link icnblk_img figpopup" rid-figpopup="figml323f5" rid-ob="figobml323f5"><img class="small-thumb" src="/books/NBK259186/bin/ml323f5.gif" src-large="/books/NBK259186/bin/ml323f5.jpg" alt="Scheme 1. Synthetic route to ML323." /></a><div class="icnblk_cntnt" id="figlgndml323f5"><h4 id="ml323.f5"><a href="/books/NBK259186/figure/ml323.f5/?report=objectonly" target="object" rid-ob="figobml323f5">Scheme 1</a></h4><p class="float-caption no_bottom_margin">Synthetic route to ML323. </p></div></div><ol class="upper-alpha"><li class="half_rhythm"><div>A solution of 2,4-dichloro-5-methylpyrimidine and 4-iodobenzylamine, HCl were dissolved in chloroform. Triethylamine was added and the sealed tube was heated at 60 ºC overnight. The reaction was purified directly by flash column chromatography (gradient elution with 0→100% ethyl acetate/hexane) to yield pure 2-chloro-5-methyl-N-(4-iodobenzyl)pyrimidin-4-amine.</div></li><li class="half_rhythm"><div>The requisite phenyl iodide was combined in a sealed tube with L-proline, sodium ascorbate, NaN<sub>3</sub>, Cu(II)SO<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub> and propiolic acid in dimethyl sulfoxide (DMSO) and water. The mixture was heated at 65 ºC overnight. The resulting mixture was quenched with a saturated aqueous ammonium chloride (NH<sub>4</sub>Cl) solution and extracted with ethyl acetate. The organic layer was washed with brine, dried with magnesium sulfate (MgSO<sub>4</sub>), and concentrated <i>in vacuo</i>. The crude product was isolated by flash column chromatography (gradient elution with 0→100% ethyl acetate/hexane) to yield pure triazole.</div></li><li class="half_rhythm"><div>The methylpyrimidine triazole derivative was combined with 2-isopropylphenylboronic acid, Palladium-tetrakis triphenylphosphine (Pd(PPh<sub>3</sub>)<sub>4</sub>), and sodium carbonate in dimethylformamide (DMF). The reaction was heated at 150 ºC for 15 min in a Biotage Initiator<sup>®</sup> microwave reactor. The resulting mixture was filtered over Celite and purified by HPLC using gradient 20-100% acetonitrile with 0.1% trifluoroacetic acid (TFA) in water with 0.1% TFA to yield pure N-(4-(1H-1,2,3-triazol-1-yl)benzyl)-5-methyl-2-(2-isopropylphenyl)pyrimidin-4-amine (<a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>) as a TFA salt after lyophilization.</div></li></ol></div></div><div id="ml323.s7"><h2 id="_ml323_s7_">3. Results</h2><div id="ml323.s8"><h3>3.1. Dose Response Curves for Probe</h3><div id="ml323.f6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%203.%20Dose%20response%20activity%20of%20ML323%20(CID%2060167849)%20in%20(A)%20SDS-PAGE%20gel%20analysis%20of%20K63-linked%20diubiquitin%20cleavage%20by%20USP1%2FUAF1%20and%20(B)%20the%20Ub-rhodamine%20qHTS%20assay%20(green%20circles)%20and%20the%20K63-linked%20diubiquitin%20gel%20assay%20(yellow%20circles).&p=BOOKS&id=259186_ml323f6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK259186/bin/ml323f6.jpg" alt="Figure 3. Dose response activity of ML323 (CID 60167849) in (A) SDS-PAGE gel analysis of K63-linked diubiquitin cleavage by USP1/UAF1 and (B) the Ub-rhodamine qHTS assay (green circles) and the K63-linked diubiquitin gel assay (yellow circles)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 3</span><span class="title">Dose response activity of ML323 (CID 60167849) in (A) SDS-PAGE gel analysis of K63-linked diubiquitin cleavage by USP1/UAF1 and (B) the Ub-rhodamine qHTS assay (green circles) and the K63-linked diubiquitin gel assay (yellow circles)</span></h3><div class="caption"><p>Results showed dose-dependent inhibition of USP1/UAF1 activity by <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> in all three assays.</p></div></div></div><div id="ml323.s9"><h3>3.2. Cellular Activity</h3><div id="ml323.f7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%204.%20Activity%20profile%20of%20the%20probe%20ML323%20showing%20treatment%20of%20human%20cells%20by%20USP1%2FUAF1%20inhibitors%20led%20to%20the%20increase%20in%20PCNA%20and%20FANCD2%20monoubiquitination.&p=BOOKS&id=259186_ml323f7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK259186/bin/ml323f7.jpg" alt="Figure 4. Activity profile of the probe ML323 showing treatment of human cells by USP1/UAF1 inhibitors led to the increase in PCNA and FANCD2 monoubiquitination." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 4</span><span class="title">Activity profile of the probe ML323 showing treatment of human cells by USP1/UAF1 inhibitors led to the increase in PCNA and FANCD2 monoubiquitination</span></h3><div class="caption"><p>HEK293T (<b>A</b> and <b>B</b>) and H596 (<b>C</b> and <b>D</b>) cells were treated with 100 µM cisplatin (lane 2), 30 µM <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> (lane 4), or in combination (lane 3). Cell lysates were analyzed by Western blotting using anti-PCNA antibody (<b>A</b> and <b>C</b>) or anti-FANCD2 antibody (<b>B</b> and <b>D</b>). The percentages of monoubiquitinated PCNA or FANCD2 were reported below each blot. <b>E</b>) Dose-dependent increase in Ub-PCNA in HCT116 cells treated with <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>.</p></div></div><div id="ml323.f8" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%205.%20Cytotoxicity%20of%20cisplatin%20and%20ML323%20tested%20as%20a%20single%20agent%20or%20in%20combination%20on%20cisplatin-resistant%20NSCLC%20cells%20(H596).&p=BOOKS&id=259186_ml323f8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK259186/bin/ml323f8.jpg" alt="Figure 5. Cytotoxicity of cisplatin and ML323 tested as a single agent or in combination on cisplatin-resistant NSCLC cells (H596)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 5</span><span class="title">Cytotoxicity of cisplatin and ML323 tested as a single agent or in combination on cisplatin-resistant NSCLC cells (H596)</span></h3><div class="caption"><p>(<b>A</b>) Cytotoxicity of cisplatin alone (<i>green diamond</i>), <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> (<i>blue triangle</i>), or a combination of cisplatin and <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> at ratios of 1:1 (<i>red circle</i>), 1:4 (<i>black square</i>) in CCK assay and (<b>C</b>) colony formation assay. (<b>B</b>) Combination index analysis of the synergistic interaction of cisplatin and (D) <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> in CCK assay and colony formation assay. Ratios of 1:1 and 1:4 were shown as <i>black triangles</i> and <i>red circles</i>, respectively. The dashed horizontal line represents a combination index = 1. Results indicated the synergistic effect of the probe <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> with cisplatin against H596 cell line.</p></div></div><div id="ml323.f9" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%206.%20Evaluation%20of%20the%20probe%20ML323%20in%20SDS-PAGE%20gel%20assays%20of%20the%20cleavage%20of%20K63-linked%20diubiquitin%20by%20(A)%20USP2%2C%20(B)%20USP5%2C%20(C)%20USP7%2C%20(D)%20USP8%2C%20and%20(E)%20USP46%2FUAF1%20in%20the%20presence%20of%20ML323.&p=BOOKS&id=259186_ml323f9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK259186/bin/ml323f9.jpg" alt="Figure 6. Evaluation of the probe ML323 in SDS-PAGE gel assays of the cleavage of K63-linked diubiquitin by (A) USP2, (B) USP5, (C) USP7, (D) USP8, and (E) USP46/UAF1 in the presence of ML323." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 6</span><span class="title">Evaluation of the probe ML323 in SDS-PAGE gel assays of the cleavage of K63-linked diubiquitin by (<b>A</b>) USP2, (<b>B</b>) USP5, (<b>C</b>) USP7, (<b>D</b>) USP8, and (<b>E</b>) USP46/UAF1 in the presence of ML323.</span></h3><div class="caption"><p>Graphical representation (<b>F</b>) of the percent inhibition of the different USPs (A-E) by <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> showed inhibitory effect only against USP1/UAF1.</p></div></div></div><div id="ml323.s10"><h3>3.3. Profiling Assays</h3><div id="ml323.f10" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%207.%20Graphical%20representation%20of%20the%20kinase%20profiling%20study%20for%20ML323%20conducted%20by%20DiscoveRx%20(KINOMEscan%02122)%20on%20a%20panel%20of%20451%20kinases.&p=BOOKS&id=259186_ml323f10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK259186/bin/ml323f10.jpg" alt="Figure 7. Graphical representation of the kinase profiling study for ML323 conducted by DiscoveRx (KINOMEscan™) on a panel of 451 kinases." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 7</span><span class="title">Graphical representation of the kinase profiling study for ML323 conducted by DiscoveRx (KINOMEscan™) on a panel of 451 kinases</span></h3><div class="caption"><p>The profiling study was done using the testing concentrations of 10 µM. See <a href="http://www.discoverx.com" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.discoverx.com</a> for details on profiling assays.</p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml323t4"><a href="/books/NBK259186/table/ml323.t4/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figml323t4" rid-ob="figobml323t4"><img class="small-thumb" src="/books/NBK259186/table/ml323.t4/?report=thumb" src-large="/books/NBK259186/table/ml323.t4/?report=previmg" alt="Table 3. ADME profile for ML323." /></a><div class="icnblk_cntnt"><h4 id="ml323.t4"><a href="/books/NBK259186/table/ml323.t4/?report=objectonly" target="object" rid-ob="figobml323t4">Table 3</a></h4><p class="float-caption no_bottom_margin">ADME profile for ML323. </p></div></div></div></div><div id="ml323.s11"><h2 id="_ml323_s11_">4. Discussion</h2><div id="ml323.s12"><h3>4.1. Comparison to Existing Art and How the New Probe is an Improvement</h3><p>A minimal number of USP1 inhibitors have been described to date. The primary compounds arising from our pilot screening efforts constitute two known bioactive molecules GW7647 and Pimozide. Both compounds possess reasonable selectivity for USP1/UAF1 (<a class="figpopup" href="/books/NBK259186/table/ml323.t5/?report=objectonly" target="object" rid-figpopup="figml323t5" rid-ob="figobml323t5">Table 4</a>) and have been shown to inactivate USP1 as well as potentiate the effects of cisplatin in cells [<a class="bibr" href="#ml323.r9" rid="ml323.r9">9</a>]. GW7647 and Pimozide facilitated proof-of-principle studies for targeting USP1, but both are limited by potency and off-target pharmacology, particularly because these compounds have annotated activity against unrelated targets. The other, non-NCGC identified, small molecule inhibitor of USP1 listed in the Prior Art is C527, which was reported by D'Andrea <i>et al</i>. in a recent patent application (Publication No. WO/2011/137320). C527 sensitizes cells to both the crosslinking agent, mitomycin C, and the topoisomerase I inhibitor, camptothecin. Although it is more potent than the previously mentioned Prior Art, C527 also has reduced selectivity compared to <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>, showing low micromolar inhibition of related USPs (<a class="figpopup" href="/books/NBK259186/table/ml323.t5/?report=objectonly" target="object" rid-figpopup="figml323t5" rid-ob="figobml323t5">Table 4</a>) as well as dissimilar DUBs (i.e. UCL-H1 and UCL-H3). With respect to potency against USP1/UAF1, <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> displayed a 5- to 10-fold increase over C527, depending on assay format. Moreover, <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> showed no activity against other related USPs compared to current prior art (<a class="figpopup" href="/books/NBK259186/table/ml323.t5/?report=objectonly" target="object" rid-figpopup="figml323t5" rid-ob="figobml323t5">Table 4</a>).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml323t5"><a href="/books/NBK259186/table/ml323.t5/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img figpopup" rid-figpopup="figml323t5" rid-ob="figobml323t5"><img class="small-thumb" src="/books/NBK259186/table/ml323.t5/?report=thumb" src-large="/books/NBK259186/table/ml323.t5/?report=previmg" alt="Table 4. Comparison of ML323 to previously identified USP1 inhibitors." /></a><div class="icnblk_cntnt"><h4 id="ml323.t5"><a href="/books/NBK259186/table/ml323.t5/?report=objectonly" target="object" rid-ob="figobml323t5">Table 4</a></h4><p class="float-caption no_bottom_margin">Comparison of ML323 to previously identified USP1 inhibitors. </p></div></div></div></div><div id="ml323.s13"><h2 id="_ml323_s13_">5. References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="ml323.r1">Pickart CM. Mechanisms underlying ubiquitination. <span><span class="ref-journal">Annu Rev Biochem. </span>2001;<span class="ref-vol">70</span>:503–533.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11395416" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11395416</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="ml323.r2">Bergink S, Jentsch S. Principles of ubiquitin and SUMO modifications in DNA repair. <span><span class="ref-journal">Nature. </span>2009;<span class="ref-vol">458</span>(7237):461–467.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19325626" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19325626</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="ml323.r3">Conaway RC, Brower CS, Conaway JW. Emerging roles of ubiquitin in transcription regulation. <span><span class="ref-journal">Science. </span>2002;<span class="ref-vol">296</span>(5571):1254–1258.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12016299" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12016299</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="ml323.r4">Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. <span><span class="ref-journal">Science. </span>2007;<span class="ref-vol">315</span>(5809):201–205.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17218518" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17218518</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="ml323.r5">Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. <span><span class="ref-journal">Nat Rev Cancer. </span>2006;<span class="ref-vol">6</span>(5):369–81.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16633365" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16633365</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="ml323.r6">McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. <span><span class="ref-journal">Drug Resist Updat. </span>2008;<span class="ref-vol">11</span>(4-5):164–179.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18818117" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18818117</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="ml323.r7">Singhal S, Taylor MC, Baker RT. Deubiquitylating enzymes and disease. <span><span class="ref-journal">BMC Biochem. </span>2008;<span class="ref-vol">9</span>(Suppl 1):S3.</span> [<a href="/pmc/articles/PMC2582804/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2582804</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19007433" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19007433</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="ml323.r8">Nijman S, Huang T, Dirac A, Brummelkamp T, Kerkhoven R, D'Andrea A, Bernards R. The Deubiquitinating Enzyme USP1 Regulates the Fanconi Anemia Pathway. <span><span class="ref-journal">Mol Cell. </span>2005;<span class="ref-vol">17</span>(3):331–339.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15694335" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15694335</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="ml323.r9">Chen J, et al. Selective and Cell – Active Inhibitors of the USP1/ UAF1 Deubiquitinase Complex Reverse Cisplatin Resistance in Non-small Cell Lung Cancer Cells. <span><span class="ref-journal">Chemistry & biology. </span>2011;<span class="ref-vol">18</span>(11):1390–400.</span> [<a href="/pmc/articles/PMC3344384/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3344384</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22118673" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22118673</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="ml323.r10">McGovern SL, et al. A specific mechanism of nonspecific inhibition. <span><span class="ref-journal">J Med Chem. </span>2003;<span class="ref-vol">46</span>(20):4265–72.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13678405" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13678405</span></a>]</div></dd></dl></dl></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>#</dt><dd><div id="ml323.fn1"><p class="no_top_margin">These authors contributed equally to this report</p></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK259186_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Thomas S. Dexheimer</span>,<sup>1</sup><sup>,<a href="#ml323.fn1">#</a></sup> <span itemprop="author">Andrew S. Rosenthal</span>,<sup>1</sup><sup>,<a href="#ml323.fn1">#</a></sup> <span itemprop="author">Qin Liang</span>,<sup>2</sup><sup>,<a href="#ml323.fn1">#</a></sup> <span itemprop="author">Junjun Chen</span>,<sup>2</sup> <span itemprop="author">Mark A. Villamil</span>,<sup>2</sup> <span itemprop="author">Edward H. Kerns</span>,<sup>1</sup> <span itemprop="author">Anton Simeonov</span>,<sup>1</sup> <span itemprop="author">Ajit Jadhav</span>,<sup>1</sup> <span itemprop="author">Zhihao Zhuang</span>,<sup>2</sup> and <span itemprop="author">David J. Maloney</span><sup>1</sup><sup>,*</sup>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup>
|
|
NIH Chemical Genomics Center, National Center for Advancing Translational Sciences, 9800 Medical Center Drive, Rockville, MD, 20850</div><div class="affiliation"><sup>2</sup>
|
|
Department of Chemistry and Biochemistry, 214A Drake Hall, University of Delaware, Newark, DE, 19716, USA</div><div class="affiliation">
|
|
<sup>*</sup> To whom correspondence should be addressed: Email:
|
|
<a href="mailto:dev@null" data-email="vog.hin.liam@dyenolam" class="oemail">vog.hin.liam@dyenolam</a></div><h3>Publication History</h3><p class="small">Received: <span itemprop="datePublished">October 23, 2012</span>; Last Update: <span itemprop="dateModified">September 18, 2014</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p>National Center for Biotechnology Information (US), Bethesda (MD)</p><h3>NLM Citation</h3><p>Dexheimer TS, Rosenthal AS, Liang Q, et al. Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex. 2012 Oct 23 [Updated 2014 Sep 18]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/mlprobe/ml328/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/mlprobe/ml327/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="fig" id="figobml323f1"><div id="ml323.f1" class="figure"><div class="graphic"><img data-src="/books/NBK259186/bin/ml323f1.jpg" alt="Image ml323f1" /></div></div></article><article data-type="table-wrap" id="figobml323t1"><div id="ml323.t1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK259186/table/ml323.t1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml323.t1_lrgtbl__"><table><thead><tr><th id="hd_h_ml323.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CID/ML#</th><th id="hd_h_ml323.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Target Name</th><th id="hd_h_ml323.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IC50/EC50 (nM) [SID, AID]</th><th id="hd_h_ml323.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anti-target Name(s)</th><th id="hd_h_ml323.t1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IC50/EC50 (mM) [SID, AID]</th><th id="hd_h_ml323.t1_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fold Selective</th><th id="hd_h_ml323.t1_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Secondary Assay(s) Name: IC50/EC50 (nM) [SID, AID]</th></tr></thead><tbody><tr><td headers="hd_h_ml323.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CID 60167849/<a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a></td><td headers="hd_h_ml323.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">USP1/UAF1</td><td headers="hd_h_ml323.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76 nM (Ub-Rho) [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/44116952" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 44116952</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651605" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651605</a>]</td><td headers="hd_h_ml323.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">USP2<br /><br />USP5<br /><br />USP7<br /><br />USP8<br /><br />USP46/UAF1</td><td headers="hd_h_ml323.t1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>114 mM [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116952" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144116952</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651605" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651626</a>];<br />>114 mM [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116952" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144116952</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651605" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651625</a>];<br />>114 mM [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116952" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144116952</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651605" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651624</a>];<br />>114 mM [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116952" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144116952</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651605" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651623</a>];<br />>114 mM [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116952" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144116952</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651605" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651622</a>];</td><td headers="hd_h_ml323.t1_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1500<br /><br />>1500<br /><br />>1500<br /><br />>1500<br /><br />>1500</td><td headers="hd_h_ml323.t1_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">174 nM (Di-Ub) [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116952" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144116952</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651621" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651621</a>]</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobml323t2"><div id="ml323.t2" class="table"><h3><span class="label">Table 1</span><span class="title">USP1/UAF1 qHTS protocol</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK259186/table/ml323.t2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml323.t2_lrgtbl__"><table class="no_top_margin"><thead><tr><th id="hd_h_ml323.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Sequence</th><th id="hd_h_ml323.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Parameter</th><th id="hd_h_ml323.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Value</th><th id="hd_h_ml323.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Description</th></tr></thead><tbody><tr><td headers="hd_h_ml323.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>1</b></td><td headers="hd_h_ml323.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Reagent</td><td headers="hd_h_ml323.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 µL</td><td headers="hd_h_ml323.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">USP1/UAF1 (1 nM final conc.) or buffer-only control</td></tr><tr><td headers="hd_h_ml323.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>2a</b></td><td headers="hd_h_ml323.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Compound</td><td headers="hd_h_ml323.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">23 nL</td><td headers="hd_h_ml323.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Compound Library</td></tr><tr><td headers="hd_h_ml323.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>2b</b></td><td headers="hd_h_ml323.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Control</td><td headers="hd_h_ml323.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">23 nL</td><td headers="hd_h_ml323.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">GW7647</td></tr><tr><td headers="hd_h_ml323.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>3</b></td><td headers="hd_h_ml323.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time</td><td headers="hd_h_ml323.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15 min</td><td headers="hd_h_ml323.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RT Incubation</td></tr><tr><td headers="hd_h_ml323.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>4</b></td><td headers="hd_h_ml323.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Reagent</td><td headers="hd_h_ml323.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 µL</td><td headers="hd_h_ml323.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Ub-Rho Substrate (150 nM final conc.)</td></tr><tr><td headers="hd_h_ml323.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>5</b></td><td headers="hd_h_ml323.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Detector</td><td headers="hd_h_ml323.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Fluorescence</td><td headers="hd_h_ml323.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ViewLux (Rhodamine optics)</td></tr><tr><td headers="hd_h_ml323.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>6</b></td><td headers="hd_h_ml323.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time</td><td headers="hd_h_ml323.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 min</td><td headers="hd_h_ml323.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RT Incubation</td></tr><tr><td headers="hd_h_ml323.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>7</b></td><td headers="hd_h_ml323.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Detector</td><td headers="hd_h_ml323.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Fluorescence</td><td headers="hd_h_ml323.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ViewLux (Rhodamine optics)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml323f2"><div id="ml323.f2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20ml323f2&p=BOOKS&id=259186_ml323f2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK259186/bin/ml323f2.jpg" alt="Image ml323f2" class="tileshop" title="Click on image to zoom" /></a></div><div class="caption"><p>*Purity >98% as determined by LC/MS and <sup>1</sup>H NMR analyses</p></div></div></article><article data-type="fig" id="figobml323f3"><div id="ml323.f3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Chemical%20stability%20of%20ML323%20measured%20as%20percent%20composition%20of%20probe%20molecule%20in%20aqueous%20solution%20at%20room%20temperature%20in%20(A)%20DPBS%20pH%207.4%20buffer%3B%20(B)%20USP1%2FUAF1%20assay%20buffer%20at%20pH%207.8%20(50%20mM%20HEPES%2C%200.5%20mM%20EDTA%2C%20100%20mM%20NaCl%2C%201%20mM%20TCEP%2C%200.1%20mg%2FmL%20BSA%2C%20and%200.01%25%20Tween-20)%3B%20(C)%20USP1%2FUAF1%20assay%20buffer%20at%20pH%202%20and%20(D)%20at%20pH%209%20buffer.&p=BOOKS&id=259186_ml323f3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK259186/bin/ml323f3.jpg" alt="Figure 1. Chemical stability of ML323 measured as percent composition of probe molecule in aqueous solution at room temperature in (A) DPBS pH 7.4 buffer; (B) USP1/UAF1 assay buffer at pH 7.8 (50 mM HEPES, 0.5 mM EDTA, 100 mM NaCl, 1 mM TCEP, 0.1 mg/mL BSA, and 0.01% Tween-20); (C) USP1/UAF1 assay buffer at pH 2 and (D) at pH 9 buffer." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Chemical stability of ML323 measured as percent composition of probe molecule in aqueous solution at room temperature in (A) DPBS pH 7.4 buffer; (B) USP1/UAF1 assay buffer at pH 7.8 (50 mM HEPES, 0.5 mM EDTA, 100 mM NaCl, 1 mM TCEP, 0.1 mg/mL BSA, and 0.01% Tween-20); (C) USP1/UAF1 assay buffer at pH 2 and (D) at pH 9 buffer</span></h3></div></article><article data-type="table-wrap" id="figobml323t3"><div id="ml323.t3" class="table"><h3><span class="label">Table 2</span><span class="title">List of the USP1/UAF1 deubiquitinase complex inhibitor probe ML323 and related analogs and their corresponding identification numbers</span></h3><div class="caption"><p>Their corresponding molecular structures are shown in <a class="figpopup" href="/books/NBK259186/figure/ml323.f4/?report=objectonly" target="object" rid-figpopup="figml323f4" rid-ob="figobml323f4">Figure 2</a>.</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK259186/table/ml323.t3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml323.t3_lrgtbl__"><table><thead><tr><th id="hd_h_ml323.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Internal ID</th><th id="hd_h_ml323.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MLS ID</th><th id="hd_h_ml323.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">SID</th><th id="hd_h_ml323.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CID</th><th id="hd_h_ml323.t3_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ML #</th><th id="hd_h_ml323.t3_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Type</th><th id="hd_h_ml323.t3_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Source</th></tr></thead><tbody><tr><td headers="hd_h_ml323.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>NCGC00262306</b></td><td headers="hd_h_ml323.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MLS004556019</td><td headers="hd_h_ml323.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116952" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">144116952</a></td><td headers="hd_h_ml323.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">60167849</td><td headers="hd_h_ml323.t3_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a></td><td headers="hd_h_ml323.t3_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Probe</td><td headers="hd_h_ml323.t3_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">NCGC</td></tr><tr><td headers="hd_h_ml323.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>NCGC00262647</b></td><td headers="hd_h_ml323.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MLS004556020</td><td headers="hd_h_ml323.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/114116970" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">114116970</a></td><td headers="hd_h_ml323.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">60167812</td><td headers="hd_h_ml323.t3_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_ml323.t3_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Analog</td><td headers="hd_h_ml323.t3_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">NCGC</td></tr><tr><td headers="hd_h_ml323.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>NCGC00253549</b></td><td headers="hd_h_ml323.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MLS004556023</td><td headers="hd_h_ml323.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116927" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">144116927</a></td><td headers="hd_h_ml323.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">60167883</td><td headers="hd_h_ml323.t3_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_ml323.t3_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Analog</td><td headers="hd_h_ml323.t3_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">NCGC</td></tr><tr><td headers="hd_h_ml323.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>NCGC00253892</b></td><td headers="hd_h_ml323.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MLS004556022</td><td headers="hd_h_ml323.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116950" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">144116950</a></td><td headers="hd_h_ml323.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">60167929</td><td headers="hd_h_ml323.t3_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_ml323.t3_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Analog</td><td headers="hd_h_ml323.t3_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">NCGC</td></tr><tr><td headers="hd_h_ml323.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>NCGC00012848</b></td><td headers="hd_h_ml323.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MLS004556021</td><td headers="hd_h_ml323.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/104223745" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">104223745</a></td><td headers="hd_h_ml323.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3235425</td><td headers="hd_h_ml323.t3_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_ml323.t3_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Analog</td><td headers="hd_h_ml323.t3_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">NCGC</td></tr><tr><td headers="hd_h_ml323.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>NCGC00253883</b></td><td headers="hd_h_ml323.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MLS004556024</td><td headers="hd_h_ml323.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/144116940" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">144116940</a></td><td headers="hd_h_ml323.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">60167905</td><td headers="hd_h_ml323.t3_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_ml323.t3_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Analog</td><td headers="hd_h_ml323.t3_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">NCGC</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml323f4"><div id="ml323.f4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%202.%20Structures%20of%20ML323%20and%20five%20other%20analogs%20that%20have%20been%20submitted%20to%20the%20MLSMR.&p=BOOKS&id=259186_ml323f4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK259186/bin/ml323f4.jpg" alt="Figure 2. Structures of ML323 and five other analogs that have been submitted to the MLSMR." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 2</span><span class="title">Structures of ML323 and five other analogs that have been submitted to the MLSMR</span></h3></div></article><article data-type="fig" id="figobml323f5"><div id="ml323.f5" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Scheme%201.%20Synthetic%20route%20to%20ML323.&p=BOOKS&id=259186_ml323f5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK259186/bin/ml323f5.jpg" alt="Scheme 1. Synthetic route to ML323." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Scheme 1</span><span class="title">Synthetic route to ML323</span></h3></div></article><article data-type="fig" id="figobml323f6"><div id="ml323.f6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%203.%20Dose%20response%20activity%20of%20ML323%20(CID%2060167849)%20in%20(A)%20SDS-PAGE%20gel%20analysis%20of%20K63-linked%20diubiquitin%20cleavage%20by%20USP1%2FUAF1%20and%20(B)%20the%20Ub-rhodamine%20qHTS%20assay%20(green%20circles)%20and%20the%20K63-linked%20diubiquitin%20gel%20assay%20(yellow%20circles).&p=BOOKS&id=259186_ml323f6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK259186/bin/ml323f6.jpg" alt="Figure 3. Dose response activity of ML323 (CID 60167849) in (A) SDS-PAGE gel analysis of K63-linked diubiquitin cleavage by USP1/UAF1 and (B) the Ub-rhodamine qHTS assay (green circles) and the K63-linked diubiquitin gel assay (yellow circles)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 3</span><span class="title">Dose response activity of ML323 (CID 60167849) in (A) SDS-PAGE gel analysis of K63-linked diubiquitin cleavage by USP1/UAF1 and (B) the Ub-rhodamine qHTS assay (green circles) and the K63-linked diubiquitin gel assay (yellow circles)</span></h3><div class="caption"><p>Results showed dose-dependent inhibition of USP1/UAF1 activity by <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> in all three assays.</p></div></div></article><article data-type="fig" id="figobml323f7"><div id="ml323.f7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%204.%20Activity%20profile%20of%20the%20probe%20ML323%20showing%20treatment%20of%20human%20cells%20by%20USP1%2FUAF1%20inhibitors%20led%20to%20the%20increase%20in%20PCNA%20and%20FANCD2%20monoubiquitination.&p=BOOKS&id=259186_ml323f7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK259186/bin/ml323f7.jpg" alt="Figure 4. Activity profile of the probe ML323 showing treatment of human cells by USP1/UAF1 inhibitors led to the increase in PCNA and FANCD2 monoubiquitination." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 4</span><span class="title">Activity profile of the probe ML323 showing treatment of human cells by USP1/UAF1 inhibitors led to the increase in PCNA and FANCD2 monoubiquitination</span></h3><div class="caption"><p>HEK293T (<b>A</b> and <b>B</b>) and H596 (<b>C</b> and <b>D</b>) cells were treated with 100 µM cisplatin (lane 2), 30 µM <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> (lane 4), or in combination (lane 3). Cell lysates were analyzed by Western blotting using anti-PCNA antibody (<b>A</b> and <b>C</b>) or anti-FANCD2 antibody (<b>B</b> and <b>D</b>). The percentages of monoubiquitinated PCNA or FANCD2 were reported below each blot. <b>E</b>) Dose-dependent increase in Ub-PCNA in HCT116 cells treated with <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a>.</p></div></div></article><article data-type="fig" id="figobml323f8"><div id="ml323.f8" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%205.%20Cytotoxicity%20of%20cisplatin%20and%20ML323%20tested%20as%20a%20single%20agent%20or%20in%20combination%20on%20cisplatin-resistant%20NSCLC%20cells%20(H596).&p=BOOKS&id=259186_ml323f8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK259186/bin/ml323f8.jpg" alt="Figure 5. Cytotoxicity of cisplatin and ML323 tested as a single agent or in combination on cisplatin-resistant NSCLC cells (H596)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 5</span><span class="title">Cytotoxicity of cisplatin and ML323 tested as a single agent or in combination on cisplatin-resistant NSCLC cells (H596)</span></h3><div class="caption"><p>(<b>A</b>) Cytotoxicity of cisplatin alone (<i>green diamond</i>), <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> (<i>blue triangle</i>), or a combination of cisplatin and <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> at ratios of 1:1 (<i>red circle</i>), 1:4 (<i>black square</i>) in CCK assay and (<b>C</b>) colony formation assay. (<b>B</b>) Combination index analysis of the synergistic interaction of cisplatin and (D) <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> in CCK assay and colony formation assay. Ratios of 1:1 and 1:4 were shown as <i>black triangles</i> and <i>red circles</i>, respectively. The dashed horizontal line represents a combination index = 1. Results indicated the synergistic effect of the probe <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> with cisplatin against H596 cell line.</p></div></div></article><article data-type="fig" id="figobml323f9"><div id="ml323.f9" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%206.%20Evaluation%20of%20the%20probe%20ML323%20in%20SDS-PAGE%20gel%20assays%20of%20the%20cleavage%20of%20K63-linked%20diubiquitin%20by%20(A)%20USP2%2C%20(B)%20USP5%2C%20(C)%20USP7%2C%20(D)%20USP8%2C%20and%20(E)%20USP46%2FUAF1%20in%20the%20presence%20of%20ML323.&p=BOOKS&id=259186_ml323f9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK259186/bin/ml323f9.jpg" alt="Figure 6. Evaluation of the probe ML323 in SDS-PAGE gel assays of the cleavage of K63-linked diubiquitin by (A) USP2, (B) USP5, (C) USP7, (D) USP8, and (E) USP46/UAF1 in the presence of ML323." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 6</span><span class="title">Evaluation of the probe ML323 in SDS-PAGE gel assays of the cleavage of K63-linked diubiquitin by (<b>A</b>) USP2, (<b>B</b>) USP5, (<b>C</b>) USP7, (<b>D</b>) USP8, and (<b>E</b>) USP46/UAF1 in the presence of ML323.</span></h3><div class="caption"><p>Graphical representation (<b>F</b>) of the percent inhibition of the different USPs (A-E) by <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> showed inhibitory effect only against USP1/UAF1.</p></div></div></article><article data-type="fig" id="figobml323f10"><div id="ml323.f10" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%207.%20Graphical%20representation%20of%20the%20kinase%20profiling%20study%20for%20ML323%20conducted%20by%20DiscoveRx%20(KINOMEscan%02122)%20on%20a%20panel%20of%20451%20kinases.&p=BOOKS&id=259186_ml323f10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK259186/bin/ml323f10.jpg" alt="Figure 7. Graphical representation of the kinase profiling study for ML323 conducted by DiscoveRx (KINOMEscan™) on a panel of 451 kinases." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 7</span><span class="title">Graphical representation of the kinase profiling study for ML323 conducted by DiscoveRx (KINOMEscan™) on a panel of 451 kinases</span></h3><div class="caption"><p>The profiling study was done using the testing concentrations of 10 µM. See <a href="http://www.discoverx.com" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.discoverx.com</a> for details on profiling assays.</p></div></div></article><article data-type="table-wrap" id="figobml323t4"><div id="ml323.t4" class="table"><h3><span class="label">Table 3</span><span class="title">ADME profile for ML323</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK259186/table/ml323.t4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml323.t4_lrgtbl__"><table class="no_margin"><thead><tr><th id="hd_h_ml323.t4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Compound</th><th id="hd_h_ml323.t4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">PBS buffer (pH 7.4) Solubility (µM)<sup>a</sup></th><th id="hd_h_ml323.t4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Log D (pH 7.4)<sup>b</sup></th><th id="hd_h_ml323.t4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Rat Liver Microsome Stability (T<sub>1/2</sub>)<sup>c</sup></th><th id="hd_h_ml323.t4_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Caco-2 (A→B) P<sub>app</sub> (10<sup>-6</sup> cm/s)<sup>d</sup></th><th id="hd_h_ml323.t4_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Caco-2 (B→A) P<sub>app</sub> (10<sup>-6</sup> cm/s)<sup>d</sup></th><th id="hd_h_ml323.t4_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Efflux Ratio</th><th id="hd_h_ml323.t4_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">PBS buffer (pH 7.4) Stability (48h)<sup>d</sup></th><th id="hd_h_ml323.t4_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Mouse Plasma Stability (2h)<sup>d</sup></th></tr></thead><tbody><tr><td headers="hd_h_ml323.t4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a></td><td headers="hd_h_ml323.t4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>86</b></td><td headers="hd_h_ml323.t4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.97</td><td headers="hd_h_ml323.t4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>12 min</b></td><td headers="hd_h_ml323.t4_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>22.98</b></td><td headers="hd_h_ml323.t4_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>20.78</b></td><td headers="hd_h_ml323.t4_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>0.90</b></td><td headers="hd_h_ml323.t4_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>99%</b></td><td headers="hd_h_ml323.t4_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>99%</b></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="ml323.tfn1"><p class="no_margin">Study was conducted by Pharmaron Inc. and was determined by LC/MS/MS.</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="ml323.tfn2"><p class="no_margin">Study was conducted by Analiza Inc. using the scaled-down shake flask lipophilicity method (see: <a href="http://www.analiza.com" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www<wbr style="display:inline-block"></wbr>​.analiza.com</a>).</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="ml323.tfn3"><p class="no_margin">The stability in the presence of NADPH was also assessed. The probe compound showed no degradation without NADPH present over a 1 hour period.</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="ml323.tfn4"><p class="no_margin">Studies were conducted at Pharmaron Inc. Results showed that <a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a> has good kinetic solubility and bioavailability indicated by a favorable results in solubility, Log D, and Caco-2 permeability.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobml323t5"><div id="ml323.t5" class="table"><h3><span class="label">Table 4</span><span class="title">Comparison of ML323 to previously identified USP1 inhibitors</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK259186/table/ml323.t5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml323.t5_lrgtbl__"><table class="no_margin"><thead><tr><th id="hd_h_ml323.t5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Compound</th><th id="hd_h_ml323.t5_1_1_1_2" colspan="6" rowspan="1" style="text-align:center;vertical-align:middle;">Biochemical Assay IC50 (µM)</th></tr><tr><th headers="hd_h_ml323.t5_1_1_1_1" id="hd_h_ml323.t5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></th><th headers="hd_h_ml323.t5_1_1_1_2" id="hd_h_ml323.t5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">USP1/UAF1</th><th headers="hd_h_ml323.t5_1_1_1_2" id="hd_h_ml323.t5_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">USP2</th><th headers="hd_h_ml323.t5_1_1_1_2" id="hd_h_ml323.t5_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">USP5</th><th headers="hd_h_ml323.t5_1_1_1_2" id="hd_h_ml323.t5_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">USP7</th><th headers="hd_h_ml323.t5_1_1_1_2" id="hd_h_ml323.t5_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">USP8</th><th headers="hd_h_ml323.t5_1_1_1_2" id="hd_h_ml323.t5_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">USP12/46</th></tr></thead><tbody><tr><td headers="hd_h_ml323.t5_1_1_1_1 hd_h_ml323.t5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="/pcsubstance/?term=ML323[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML323</a></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0.076<sup>a</sup><br />0.177<sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td></tr><tr><td headers="hd_h_ml323.t5_1_1_1_1 hd_h_ml323.t5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>GW7647</b></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">5<sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">>114<sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">44<sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">12<sup>b</sup></td></tr><tr><td headers="hd_h_ml323.t5_1_1_1_1 hd_h_ml323.t5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>Pimozide</b></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">2<sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">47<sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>NI</i><sup>b</sup></td></tr><tr><td headers="hd_h_ml323.t5_1_1_1_1 hd_h_ml323.t5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>C527</b></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0.88<sup>a</sup><sup>,</sup><sup>c</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>ND</i></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">1.65<sup>a</sup><sup>,</sup><sup>c</sup></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>ND</i></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><i>ND</i></td><td headers="hd_h_ml323.t5_1_1_1_2 hd_h_ml323.t5_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">5.97<sup>a</sup><sup>,</sup><sup>c</sup></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="ml323.tfn5"><p class="no_margin">Fluorogenic assay;</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="ml323.tfn6"><p class="no_margin">Diubiquitin assay;</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="ml323.tfn7"><p class="no_margin">Data from patent (Publication No. WO/2011/137320);</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div id="ml323.tfn8"><p class="no_margin"><i>ND</i>: Not determined; <i>NI</i>: No significant inhibition was observed at the highest inhibitor concentration of 114 µM.</p></div></dd></dl></dl></div></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript" src="/core/mathjax/2.7.9/MathJax.js?config=TeX-AMS-MML_SVG"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|